TORONTO, Feb. 11 /CNW Telbec/ - Island Labs, a leader in natural dermatological products, would like to clarify confusion regarding statements made in the press release dated January 22, 2010. The approval process in Health Canada for Natural Health Products (NHP) involves a "risk mitigation" approach to compliance and en-forcement relating to unlicensed NHPs. This approach enables Health Canada to focus compliance and enforcement efforts on NHPs that present a risk to health, without restricting access to NHPs that are awaiting review and assessment of their license applications. Under this compliance and enforcement approach, action is taken (e.g. requesting NHPs to be removed from store shelves) specifically when an unacceptable risk to health is identified and/or when the unlicensed product does not currently have a product license application under assessment at Health Canada.
Stemcelex is approved by Island Labs for commercialization, and has a product license application under assessment at Health Canada. No unacceptable risks have been identified by either Island Labs or Health Canada for the Stemcelex products and are now pending commercialization.
SOURCE ISLAND LABORATORIES INC.
For further information: For further information: Robert Tulk, (709) 634-2724, firstname.lastname@example.org